Amgen’s dazodalibep Phase 3 trial clears Sjögren’s hurdleBy Martin Holloway22/09/2026 Amgen’s dazodalibep Phase 3 trial met its primary endpoint in systemic Sjögren’s disease, sending AMGN shares higher on 22 September 2026.
